Serum Calprotectin and B-cell activating factor are potential biomarkers for Helicobacter pylori infection
https://doi.org/10.4081/jbr.2023.10803
Accepted: March 2, 2023
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Humans always mount a robust immune response to the bacterial infection caused by Helicobacter pylori, which causes various gastrointestinal tract infections. Calprotectin (CALP) and B-Cell Activating Factor (BAFF) are inflammatory biomarkers having a role in the gastrointestinal neutrophilic response to bacterial infection. The study was designed to assess serum CALP and BAFF as inflammatory biomarkers in H. pylori infection and peptic ulcer patients. The current study comprised 112 people, including 62 H. pylori-infected patients (34 men and 28 women) who were clinically diagnosed with H. pylori infection via testing positive for the H. pylori stool antigen test; they were compared to a control group of 50 healthy people (34 men and 16 women) who were age and gender- matched to H. pylori-infected patients. The serum level of CALP and BAFF were assayed using the ELISA technique. The biochemical parameters were statistically compared between patients and controls by unpaired Man-Whitney U t-test and Receiver Operating Characteristic (ROC) curve analysis. There was a significant elevation of serum CALP in H. pylori-infected patients [116.4(120.7), p=0.0132] in comparison to healthy controls [99.50(115.8)]. Similarly, there was a significant elevation of serum BAFF concentration in H. pylori-infected patients [485.7(367.1), p=0.0014] in comparison to healthy controls [444.5(513.0)]. The ROC curve analysis suggests serum CALP and BAFF as reasonable inflammatory biomarkers for H. pylori infection with statistically significant (p=0.0135, p=0.0015) area under the ROC curve of (0.6361, 0.6748), respectively. CALP and BAFF are potent inflammatory biomarkers involved in the development and etiology of H. pylori infection. Serum CALP and BAFF levels could be used as biomarkers for chronic inflammation induced by H. pylori. CALP and BAFF biomarkers can be combined to diagnose and predict the prognosis of H. pylori infection.
McColl KE. Helicobacter pylori infection. N Engl J Med 2010;362:1597-604. DOI: https://doi.org/10.1056/NEJMcp1001110
Lauwers GY, Mino-Kenudson M, Kradin RL. Infections of the gastrointestinal tract. Diagn Microbiol Infect Dis 2018:232-71. DOI: https://doi.org/10.1016/B978-0-323-44585-6.00010-2
Ishaq S, Nunn L. Helicobacter pylori and gastric cancer: a state of the art review. Gastroenterol Hepatol Bed Bench 2015;8:S6-S14.
Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-86. DOI: https://doi.org/10.1056/NEJMra020542
Kusters JG, Van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006;19:449-90. DOI: https://doi.org/10.1128/CMR.00054-05
Kopi TA, Shahrokh S, Mirzaei S, et al. The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: a review study. Gastroenterol Hepatol Bed Bench 2019;12:183.
Kalla R, Kennedy NA, Ventham NT, et al. Serum calprotectin: a novel diagnostic and prognostic marker in inflammatory bowel diseases. Am J Gastroenterol 2016;111:1796-805. DOI: https://doi.org/10.1038/ajg.2016.342
Hassan SH, Jasim BS, AL-Nasrawii MS. Assessment of Calprotectin protein in H. pylori positive persons. Indian J Forensic Med Toxicol 2020;14:903.
Dhas DBB, Bhat BV, Gane DB. Role of calprotectin in infection and inflammation. Curr Pediatr Res 2012;16:83-94.
Fodor I, Serban O, Serban DE, et al. B cell-activating factor (BAFF) in children with inflammatory bowel disease. Pediatric Res 2021;89:1798-803. DOI: https://doi.org/10.1038/s41390-020-01155-1
Liu Z, Davidson A. BAFF and selection of autoreactive B cells. Trends Immunol 2011;32:388-94. DOI: https://doi.org/10.1016/j.it.2011.06.004
Eldin AB, Sayed S, Hegazy G, Shaker O. B-Cell Activating Factor (BAFF) in systemic lupus erythematosus, rheumatoid arthritis, and Behçet's disease. Arch Rheumatol 2012;27:185-94. DOI: https://doi.org/10.5606/tjr.2012.031
Zhang P, Liu X, Guo A, Xiong J, et al. B Cell-Activating Factor as a new potential marker in Inflammatory Bowel Disease. Dig Dis Sci 2016;61:2608-18. DOI: https://doi.org/10.1007/s10620-016-4136-z
Striz I. B Cell-Activating Factor (BAFF) in Inflammatory Bowel Disease: BAFFling No Longer? Dig Dis Sci 2016;61:2456-8. DOI: https://doi.org/10.1007/s10620-016-4231-1
Mori A, Mitsuyama K, Sakemi R, et al. Evaluation of serum calprotectin levels in patients with inflammatory bowel disease. Kurume Med J 2021;66:209-15. DOI: https://doi.org/10.2739/kurumemedj.MS664009
Mari A, Baker FA, Mahamid M, et al. Clinical utility of fecal calprotectin: potential applications beyond inflammatory bowel disease for the primary care physician. Ann Gastroenterol 2019;32:425-30. DOI: https://doi.org/10.20524/aog.2019.0394
Rafeey M, Nikmanesh P, Javadzadeh F. Diagnostic value of fecal calprotectin in children with gastritis, duodenitis and Helicobacter pylori. Int J Prev Med 2022;13:107.
Demirbaş F, Çaltepe G, Abbasguliyev H, Kalaycı AG. Fecal calprotectin levels used as a noninvasive method for screening for chronic gastritis in pediatric patients. A descriptive study. Sao Paulo Med J 2021;139:564-9. DOI: https://doi.org/10.1590/1516-3180.2020.0765.r1.0904221
Koninckx CR, Donat E, Benninga MA, et al. The use of fecal calprotectin testing in paediatric disorders: a position paper of the European Society for Paediatric Gastroenterology and Nutrition Gastroenterology committee. J Pediatr Gastroenterol Nutr 2021;72:617-40. DOI: https://doi.org/10.1097/MPG.0000000000003046
Aksoy ÖY, Canan O, Hoşnut FÖ, et al. Fecal calprotectin levels in Helicobacter pylori gastritis in children. Turk J Pediatr 2020;62:986-93. DOI: https://doi.org/10.24953/turkjped.2020.06.010
Daniluk U, Daniluk J, Krasnodebska M, et al. The combination of fecal calprotectin with ESR, CRP and albumin discriminates more accurately children with Crohn’s disease. Adv Med Sci 2019;64:9-14. DOI: https://doi.org/10.1016/j.advms.2018.08.001
Hare N, Kennedy N, Kingstone K, et al. PTH-082 Serum Calprotectin: a novel biomarker to predict outcome in Acute Severe Ulcerative Colitis? Gut 2013;62:A244-5. DOI: https://doi.org/10.1136/gutjnl-2013-304907.569
Meuwis M-A, Vernier-Massouille G, Grimaud JC, et al. Serum calprotectin as a biomarker for Crohn's disease. J Crohns Colitis 2013;7:e678-83. DOI: https://doi.org/10.1016/j.crohns.2013.06.008
Wang S, Wang Z, Shi H, et al. Faecal calprotectin concentrations in gastrointestinal diseases. Int J Med Res 2013;41:1357-61. DOI: https://doi.org/10.1177/0300060513488499
Özşeker B, Şahin C, Özşeker HS, et al. The role of fecal calprotectin in evaluating intestinal involvement of Behçet’s disease. Dis Markers 2016;2016:5423043. DOI: https://doi.org/10.1155/2016/5423043
Ataee P, Afrasiabi V, Nikkhoo B, et al. Relationship between fecal calprotectin and upper endoscopy findings in children with upper gastrointestinal symptoms. Iran J Pediatr 2017;27:e8658. DOI: https://doi.org/10.5812/ijp.8658
Jiménez-Soto LF, Haas R. The CagA toxin of Helicobacter pylori: abundant production but relatively low amount translocated. Sci Rep 2016;6:23227. DOI: https://doi.org/10.1038/srep23227
Gaddy JA, Radin JN, Cullen TW, et al. Helicobacter pylori resists the antimicrobial activity of calprotectin via lipid A modification and associated biofilm formation. MBio 2015;6:e01349-15. DOI: https://doi.org/10.1128/mBio.01349-15
Gaddy JA, Radin JN, Loh JT, et al. The host protein calprotectin modulates the Helicobacter pylori cag type IV secretion system via zinc sequestration. PLoS Pathog 2014;10:e1004450. DOI: https://doi.org/10.1371/journal.ppat.1004450
Kumric M, Zivkovic PM, Ticinovic Kurir TT, et al. Role of B-Cell Activating Factor (BAFF) in Inflammatory Bowel Disease. Diagnostics 2022;12:45. DOI: https://doi.org/10.3390/diagnostics12010045
Lied GA, Berstad A. Functional and clinical aspects of the B-Cell-Activating Factor (BAFF): a narrative review. Scand J Immunol 2011;73:1-7. DOI: https://doi.org/10.1111/j.1365-3083.2010.02470.x
Zhang Y, Tian J, Xiao F, et al. B cell-activating factor and its targeted therapy in autoimmune diseases. Cytokine Growth Factor Rev 2022;64:57-70. DOI: https://doi.org/10.1016/j.cytogfr.2021.11.004
Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 2006;15:570-6. DOI: https://doi.org/10.1177/0961203306071871
Nezos A, Papageorgiou A, Fragoulis G, et al. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. J Autoimmun 2014;51:89-98. DOI: https://doi.org/10.1016/j.jaut.2013.04.005
Möckel T, Basta F, Weinmann-Menke J, Schwarting A. B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). Autoimmun Rev 2021;20:102736. DOI: https://doi.org/10.1016/j.autrev.2020.102736
Fu Y, Wang L, Xie C, et al. Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation. Sci Rep 2017;7:2669. DOI: https://doi.org/10.1038/s41598-017-02835-5
Uzzan M, Colombel J-F, Cerutti A, et al. B Cell-Activating Factor (BAFF)-targeted B Cell therapies in Inflammatory Bowel Diseases. Dig Dis Sci 2016;61:3407-24. DOI: https://doi.org/10.1007/s10620-016-4317-9
Wu X, Li X, Dang Z, Jia Y. Berberine demonstrates anti-inflammatory properties in Helicobacter pylori-infected mice with chronic gastritis by attenuating the Th17 response triggered by the B cell-activating factor. J Cell Biochem 2018;119:5373-81. DOI: https://doi.org/10.1002/jcb.26681
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
